BioNTech


Management focus is on a strong balance sheet

20/11/23 -"After the fairly decent Q3 results and the guidance cut on costs, a mix of lower operating costs, higher interest income (again) and a lower tax rate have all driven an upgrade to our 2023 EPS ..."

Pages
57
Language
English
Published on
20/11/23
You may also be interested by these reports :
12/12/24
Lonza conducted a well-attended investor update, positioned between a standard analyst presentation and an investor or capital markets day. Key ...

12/12/24
After integrating the latest financial figures, we have further reduced the operating expense (opex) forecast for 2024. The impact is however minimal ...

09/12/24
Lonza shares (Add; Switzerland) have experienced significant growth over the past decade, peaking in 2022. The appointment of Mr Ridinger was ...

09/12/24
With some of AstraZeneca’s key executives in China being under investigation by the local authorities, the shares have experienced negative momentum ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO